Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BHQ880 · 3 trials · 4 indications
Time to first SRE from randomization
| Arm | Type | Description |
|---|---|---|
| BHQ880 + bortezomib and dexamethasone | EXPERIMENTAL | - |
| BHQ880 Placebo + bortezomib and dexamethasone | PLACEBO_COMPARATOR | - |
| BHQ880 | EXPERIMENTAL | - |
| BHQ880 + zoledronic acid | EXPERIMENTAL | BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| BHQ880 | DRUG | - |
| BHQ880 Placebo | DRUG | Intravenous infusion |
| bortezomib | DRUG | intravenous injection |
| dexamethasone | DRUG | Oral |
| Zoledronic acid | DRUG | - |
Inclusion Criteria: 1. Confirmed diagnosis of multiple myeloma 2. Life expectancy of more than 6 months in the absence of intervention 3. Must not have received previous or be receiving current antimyeloma therapies 4. Renal insufficiency 5. Recovered from the effects of any prior surgery or radiot...
Top 20 of 25 competitors
BHQ880 is an investigational drug being studied for use in multiple myeloma bone disease, smoldering multiple myeloma, and multiple myeloma. It is being developed by Novartis AG (NVS) as a small molecule oncology treatment. Clinical trials have evaluated it in patients with relapsed or refractory myeloma, high risk smoldering myeloma, and untreated myeloma with renal insufficiency.
BHQ880 is being developed by Novartis AG, which trades under the ticker NVS. The company has sponsored clinical trials of BHQ880 in multiple myeloma and related conditions. All trials of BHQ880 listed in clinical registries are completed, with no active trials currently ongoing.
BHQ880 is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials in multiple myeloma and smoldering multiple myeloma. The drug is investigational and has not been approved by regulatory authorities. All three registered clinical trials for BHQ880 are completed.
BHQ880 has been studied in three completed clinical trials: NCT00741377, a Phase 1 study in relapsed or refractory myeloma patients; NCT01302886, a Phase 2 study in high risk smoldering multiple myeloma; and NCT01337752, a Phase 2 study in untreated multiple myeloma with renal insufficiency. Total enrollment across these trials was 78 patients.
BHQ880 is the primary name used for this investigational drug in clinical trials and regulatory documents. No alternative names have been identified for BHQ880 in the available clinical trial information. The drug is a small molecule being developed by Novartis for multiple myeloma and related bone disease.